{"id":"W2504623699","doi":"10.1016/s1470-2045(16)30167-x","title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":924,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto","funders":"NIHR Oxford Biomedical Research Centre; National Institutes of Health; National Cancer Institute; National Institute for Health and Care Research; Bristol-Myers Squibb","keywords":"Brentuximab vedotin; Medicine; Nivolumab; Internal medicine; Oncology; Autologous stem-cell transplantation; Clinical endpoint; Transplantation; Lymphoma; Surgery; Clinical trial; Hodgkin lymphoma; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03356002623975395,"score_gpt":0.3124283474722595,"score_spread":0.2788683212325055,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}